Breaking News, Collaborations & Alliances

Veloxis, Athena in Cholesterol Combo-Pact

Athena to market Lipitor-Tricor fixed dose in emerging markets

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Veloxis Pharmaceuticals and Athena Drug Delivery Solutions have entered an alliance in which Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis’ AtorFen. AtorFen is an oral tablet combination of fenofibrate (Tricor) and atorvastatin (Lipitor), containing the lowest fully effective dose of fenofibrate. The product has been developed by Veloxis through Phase II in the US. Results show...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters